(4-{4-Amino-1-[4-(4-methyl-piperazin-1-yl)-cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxy-phenyl)-carbamic acid tert-butyl ester | 330793-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (4-{4-Amino-1-[4-(4-methyl-piperazin-1-yl)-cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxy-phenyl)-carbamic acid tert-butyl ester
• CAS: 330793-47-0
• 化学式: C₂₈H₄₀N₈O₃
• 分子量: 536.677
• InChiKey: HQTXCWQEZQPMOW-MXVIHJGJSA-N

物化性质

• 沸点：
  678.3±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.16
• 重原子数：
  39.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  123.66
• 氢给体数：
  2.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  (4-{4-Amino-1-[4-(4-methyl-piperazin-1-yl)-cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxy-phenyl)-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck — a selectivity insight

  摘要：

  A series of para-substituted 3-phenyl pyrazolopyrimidines was synthesized and evaluated as inhibitors of lck. The nature of the substitution affected enzyme selectivity and potency for lck, src, kdr, and tie-2. The para-phenoxyphenyl analogue 2 is an orally active lck inhibitor with a bioavailability of 69% and exhibits an extended duration of action in animal models of T cell inhibition. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00196-8
• 作为产物：
  描述：

  4-氨基吡唑并[3,4-d]嘧啶 在 盐酸 、 N-碘代丁二酰亚胺 、 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 溶剂黄146 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 (4-{4-Amino-1-[4-(4-methyl-piperazin-1-yl)-cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxy-phenyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck — a selectivity insight

  摘要：

  A series of para-substituted 3-phenyl pyrazolopyrimidines was synthesized and evaluated as inhibitors of lck. The nature of the substitution affected enzyme selectivity and potency for lck, src, kdr, and tie-2. The para-phenoxyphenyl analogue 2 is an orally active lck inhibitor with a bioavailability of 69% and exhibits an extended duration of action in animal models of T cell inhibition. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00196-8

文献信息

• Pyrazolopyrimidines as therapeutic agents
  申请人：Abbott Laboratories

  公开号：US20020156081A1

  公开（公告）日：2002-10-24

  The present invention provides compounds of Formula I, 1 including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R 2 , and R 3 are defined as described herein.

  本发明提供了公式I的化合物，包括其药学上可接受的盐和/或前药，其中G、R2和R3的定义如本文所述。
• Method of identifying inhibitors of Lck
  申请人：——

  公开号：US20030175935A1

  公开（公告）日：2003-09-18

  The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.

  本发明涉及包含Lck配体结合域的多肽、这些多肽的结晶形式，以及使用这些结晶形式来确定Lck催化域的三维结构。本发明还涉及使用Lck催化域的三维结构，单独或与抑制剂复合物一起，设计和/或识别Lck活性的潜在抑制剂的方法，例如抑制天然底物与Lck催化域的结合的化合物。本发明还涉及使用Lck催化域的三维结构，单独或与抑制剂复合物一起，设计和/或识别Lck活性的潜在选择性抑制剂的方法，例如选择性抑制天然底物与Lck催化域的结合的化合物。
• PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1212327B1

  公开（公告）日：2003-08-20
• US6660744B1
  申请人：——

  公开号：US6660744B1

  公开（公告）日：2003-12-09
• US6921763B2
  申请人：——

  公开号：US6921763B2

  公开（公告）日：2005-07-26